<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00672867</url>
  </required_header>
  <id_info>
    <org_study_id>L-FMAU-309</org_study_id>
    <nct_id>NCT00672867</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Evaluate the Safety and Efficacy of Clevudine or Adefovir Patients With LC-B</brief_title>
  <official_title>A Open Randomized Clinical Trial Comparing the Efficacy and Safety of Clevudine 30mg Versus Adefovir 10mg in Patients With LC-B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bukwang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bukwang Pharmaceutical</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and antiviral activity of Clevudine Versus
      Adefovir dipivoxil in patients with LC-B.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with HBV DNA below 12 IU/mL by Real-Time PCR</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of HBV DNA from the baseline.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child-Pugh score improvement</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MELD score improvement</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical improvement</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with HBeAg loss and/or seroconversion</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Patients With LC-B</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clevudine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adefovir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clevudine</intervention_name>
    <description>30mg</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Levovir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir dipivoxil</intervention_name>
    <description>10mg</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Hepsera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is 18 years and older.

          2. 5 ≦ Child-Pugh score ≦ 12

          3. Patient is HBV DNA positive with DNA levels ≥ 1 x 10(4) copies/mL within 30 days of
             baseline.

          4. Patient is documented to be HBsAg positive for &gt; 6 months.

          5. Patient is HBeAg positive or negative.

          6. Patient has ALT or AST levels which are in the range of ＞ 1 x ULN and &lt; 15 X ULN

          7. Patient with liver cirrhosis diagnosed by imaging study within 1 year or clinical
             evidence of portal hypertension

          8. Life expectancy of at least 12 months

          9. Female patient with a negative urine(Beta-HCG) pregnancy test taken within 14 days of
             starting therapy.

         10. Patient who is able to give written informed consent prior to study start and to
             comply with the study requirements.

        Exclusion Criteria:

          1. Patient is currently receiving antiviral, immunomodulatory, cytotoxic or
             corticosteroid therapy.

          2. Previous treatment with interferon must have ended at least 6 months prior to the
             screening visit.

          3. Patients previously treated with clevudine, entecavir, lamivudine, adefovir,
             telbivudine or any other investigational nucleoside for HBV infection.

          4. Patient is coinfected with HCV, HDV or HIV.

          5. Patient with clinical evidence of hepatocellular carcinoma

          6. Patient has alpha-fetoprotein &gt; 400ng/mL.

          7. Patient has Hemoglobin &lt;8g/dL (Male), 7.5g/dL (Female) or WBC &lt;1,500mm3 or Neutrophils
             &lt;500/mm3 or Platelet count &lt;30,000/mm3.

          8. Patient is pregnant or breast-feeding.

          9. Patient is unwilling to use an &quot;effective&quot; method of contraception during the study
             and for up to 3 months after the use of study drug ceases.

         10. Patient has a clinically relevant history of abuse of alcohol or drugs.

         11. Patient with previous liver transplantation

         12. Patient has a significant immunocompromised, gastrointestinal, renal, hematological,
             psychiatric, bronchopulmonary, biliary diseases excluding asymptomatic GB stone,
             neurological, cardiac, oncologic(except HCC)or allergic disease or medical illness
             that in the investigator's opinion might interfere with therapy.

         13. Patient has creatinine clearance less than 60mL/min as estimated by the following
             formula: (140-age in years) (body weight [kg])/(72) (serum creatinine [mg/dL]) [Note:
             multiply estimates by 0.85 for women]
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2008</study_first_submitted>
  <study_first_submitted_qc>May 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2008</study_first_posted>
  <last_update_submitted>December 17, 2014</last_update_submitted>
  <last_update_submitted_qc>December 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2014</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Clevudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

